Characteristics and Outcomes of patients treated with CDK4/6 inhibitors who develop interstitial lung disease

Résumé fourni par la source

CDK4/6 inhibitors have become a cornerstone in the treatment of breast cancer. A serious adverse effect that has been noted with these drugs is the development of drug-associated interstitial lung disease. Our objective was to compare the cohort of patients on CDK4/6 inhibitors who developed ILD within 3 years of starting the drug with the cohort of patients on CDK4/6 inhibitors who did not develop ILD, to determine if there were any significant differences in baseline characteristics and outcomes between these groups. Adults (>18 years old) in the US who were treated with CDK4/6 inhibitors were identified using the TriNetX database. Two cohorts were defined based on presence or absence of ICD-10 codes for ILD (J70.2, J84) and their baseline characteristics were compared. Before performing outcome analysis the two cohorts underwent propensity score matching for age, sex, history of nicotine dependence, pulmonary and cardiac disease. 31,238 patients who were on CDK4/6 therapy were identified - of them, 794 had developed ILD within 3 years of starting therapy. The cohort that developed ILD had a significantly higher risk of death (+8.6%, p=0.0003) and hospitalization (+22.5%, p<0.0001). We found a significant difference in rates of nicotine dependence, obesity, hypertension and hyperlipidemia between the groups at baseline. These data may help stratify patients who are at increased risk of complications with treatment with CDK4/6 inhibtiors.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.